CARSGEN-B: PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE ADOPTION OF THE EIGHTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
CARSGEN-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
CARSGEN-B: Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
CARSGEN-B: Letter to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
CARSGEN-B: DATE OF BOARD MEETING
CARSGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
CARSGEN-B: INSIDE INFORMATION ANNOUNCEMENT - THE NMPA APPROVES THE BCMA CAR-T THERAPY ZEVORCABTAGENE AUTOLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE PROGRESSED AFTER AT LEAST 3 PRIOR LINES OF THERAPY (I
CARSGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
CARSGEN-B: VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON CT041 AT 2024 ASCO GI MEETING
CARSGEN-B: VOLUNTARY ANNOUNCEMENT - CT011 ACHIEVED IND CLEARANCE FROM THE NMPA FOR PATIENTS WITH GPC3-POSITIVE STAGE IIIa HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION
CARSGEN-B: CHANGE OF AUDITOR
CARSGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
CARSGEN-B: VOLUNTARY ANNOUNCEMENT - INTENTION OF SUBSTANTIAL SHAREHOLDERS TO INCREASE SHAREHOLDING IN THE COMPANY
CARSGEN-B: INSIDE INFORMATION ANNOUNCEMENT - CLINICAL HOLD IN THE U.S. DUE TO CMC RELATED QUESTIONS
CARSGEN-B: VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON ZEVOR-CEL AT 2023 ASH ANNUAL MEETING
CARSGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
CARSGEN-B: VOLUNTARY ANNOUNCEMENT - CT071 RECEIVED IND CLEARANCE FROM THE FDA FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR RELAPSED/REFRACTORY PRIMARY PLASMA CELL LEUKEMIA
CARSGEN-B: (I) GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME; AND (II) GRANT OF RSUS PURSUANT TO THE POST-IPO RSU SCHEME
CARSGEN-B: VOLUNTARY ANNOUNCEMENT - ABSTRACT OF CT041 ACCEPTED FOR POSTER PRESENTATION AT 2024 ASCO GI
CARSGEN-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
No Data